Hodgkin lymphoma: From molecular pathogenesis to targeted therapy

Ádám Jóna, A. Illés, Anas Younes

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Hodgkin lymphoma (HL) is a rare human B-cell lymphoid malignancy representing 11.4 % of all lymphomas in the United States (Jemal et al. 2009) and with an incidence rate of 2.2 per 100,000 in the more developed countries. (Jemal et al. 2011). The treatment of patients with relapsed and refractory HL, especially those who have disease relapse after autologous stem cell transplantation, remains challenging. However current therapy is expected to cure more than 80 % of these patients.

Original languageEnglish
Title of host publicationHematologic Cancers
Subtitle of host publicationFrom Molecular Pathobiology to Targeted Therapeutics
PublisherSpringer Netherlands
Pages181-202
Number of pages22
ISBN (Electronic)9789400750289
ISBN (Print)9789400750272
DOIs
Publication statusPublished - Jan 1 2012

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Hodgkin lymphoma: From molecular pathogenesis to targeted therapy'. Together they form a unique fingerprint.

  • Cite this

    Jóna, Á., Illés, A., & Younes, A. (2012). Hodgkin lymphoma: From molecular pathogenesis to targeted therapy. In Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics (pp. 181-202). Springer Netherlands. https://doi.org/10.1007/978-94-007-5028-9_10